Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema

Current Diabetes Reviews

Volumn 5, Issue 1, 2009, Pages 33-38

  Giuliari, Gian P ^a   Guel, David A ^a   Gonzalez, Victor H ^a  

^a Valley Retina Institute   (United States)

Author keywords

Diabetes mellitus; Diabetic macular edema; Pegaptanib sodium (Macugen); Proliferative diabetic retinopathy

Indexed keywords

ANGIOGENESIS INHIBITOR; PEGAPTANIB; VASCULOTROPIN; APTAMER; VASCULOTROPIN A;

ANTIANGIOGENIC THERAPY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE COURSE; EYE DISEASE; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VISUAL IMPAIRMENT; FLUORESCENCE ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA MACULA EDEMA;

APTAMERS, NUCLEOTIDE; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR EDEMA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65549120576     PISSN: 15733998     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339909787314158     Document Type: Review

References (54)

1. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82: 844-51.
2. Kempen JH, O'Colmain BJ, Leske MC, et al. For the eye diseases prevalence research group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122: 552-63.
3. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003; 26: 2653-64.
4. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. Curr Drug Targets 2005; 6: 511-24.
5. Ng EW, Adamis AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005; 40: 352-68.
6. Cogan D, Toussaint, D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66: 366-78.
7. DeVenecia G, Davis M, Engerman R. Clinicopathologic correlations in diabetic retinopathy. I. Histology and fluorescein angiography of microaneyrysms. Arch Ophthalmol 1976; 94: 1766-73.
8. Muraoka K, Shimizu K. Intraretinal neovascularization in diabetic retinopathy. Ophthalmology 1984; 91: 1440-6.
9. Patz A. Clinical and experimental studies on retinal neovascularization. XXXIX Edward Jackson Memorial Lecture. Am J Ophthalmol 1982; 94: 715-43.
10. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003; 19: 442-55.
11. Miyamoto K, Hiroshiba N, Tsujikawa A, et al. In vivo demonstration of increased leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 1998; 39: 2190-4.
12. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr Opin Ophthalmol 2004; 15: 508-18.
13. Hippenstiel S, Krüll M, Ikemann A, et al. VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 1998; 274: L678-84.
14. Gardner TW, Antonetti DA, Barber AJ, et al. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 2002; 47(Suppl 2): S253-62.
15. Ben-Mahmud BM, Chan WH, Abdulahad RM, et al. Clinical validation of a link between TNF-alpha and the glycosylation enzyme core 2 GlcNAc-T and the relationship of this link to diabetic retinopathy. Diabetologia 2006; 49: 2185-91.
16. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579-88.
17. Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefe's Arch Clin Exp Ophthalmol 2005; 243: 593-600.
18. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-75.
19. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219-24.
20. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112: 806-16.
21. Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999; 14: 223-32.
22. Tolentino MJ, Miller JW, Gragoudas ES, et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103: 1820-8.
23. Tolentino MJ, McLeod DS, Taomoto M, et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 2002; 133: 373-85.
24. Brooks HL Jr, Caballero S Jr, Newell CK, et al. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch Ophthalmol 2004; 122: 1801-7.
25. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331: 1480-7.
26. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
27. Boulton M, Foreman D, Williams G, McLeod D. VEGF localisation in diabetic retinopathy. Br J Ophthalmol 1998; 82: 561-8.
28. Funatsu H, Yamashita H, Shimizu E, et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina 2001; 21: 469-77.
29. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006; 5: 123-32.
30. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR, for the VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
31. Chakravarthy U, Adamis AP, Cunningham ET Jr, et al, for the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508.e1-25.
32. D'Amico DJ, Masonson HN, Patel M, et al, for the VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006; 113: 992-1001.
33. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198: 483-9.
34. Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112: 1747-57.
35. Adamis AP, Altaweel M, Bressler NM, et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006; 113: 23-8.
36. Ishida S, Usui T, Yamashiro K, et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003; 44: 2155-62.
37. Su Y-TJ, Gonzalez VH, Vann VR, et al. Pegaptanib Sodium (Macugen®) as an Adjunct in the Management of Refractory Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema. Presented at the 2007 annual meeting of the Association for Research in Vision and Ophthalmology, May 07, Fort Lauderdale, Florida. Paper Session 225.
38. Gonzalez VH, Vann VR, Banda RM. Use of Pegaptanib Sodium (Macugen®) for the Regression of Proliferative Diabetic Retinopathy. Presented at the 2006 annual meeting of the Association for Research in Vision and Ophthalmology, May 02, Fort Lauderdale, Florida. Paper Session 312.
39. Early Treatment Diabetic Retinopathy Study Research Group. ETDRS report no. 2: treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Ophthalmology 1987; 94: 761-74.
40. Early Treatment Diabetic Retinopathy Study Research Group. Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS report no. 3. Int Ophthalmol Clin 1987; 274: 254-64.
41. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical applications of Diabetic Retinopathy Study. DRS Report number 8. Ophthalmology 1981; 88: 583-600.
42. Blankenship GW. Diabetic retinopathy, present and future. Conclusion of diabetic retinopathy symposium. Ophthalmology 1981; 88: 658-61.
43. Khosla PK, Talwar D, Tewari HK. Contrast sensitivity changes in background diabetic retinopathy. Can J Ophthalmol 1991; 26: 7-11.
44. Kleiner RC, Elman MJ, Murphy RP, Ferris FL 3rd. Transient severe visual loss after panretinal photocoagulation. Am J Ophthalmol 1988; 106: 298-306.
45. Meyers SM. Macular edema after scatter laser photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol 1980; 90: 210-16.
46. Guyer DR, D'Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 652-6.
47. Han DP, Mieler WF, Burton TC. Submacular fibrosis after photocoagulation for diabetic macular edema. Am J Ophthalmol 1992; 113: 513-21.
48. Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology 1990; 97: 503-10.
49. Coyne KS, Margolis MK, Kennedy-Martin T, et al. The impact of diabetic retinopathy: perspectives from the patient focus groups. Fam Pract 2004; 21: 447-53.
50. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
51. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 16: 851-8.
52. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-12.
53. Shima DT, Adamis AP, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Mol Med 1995; 1: 182-93.
54. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995; 113: 1538-44.